Howard Gurney

Professor Howard Gurney is a leading academic and clinician at Macquarie University, serving as Director of Clinical Trials and Head of the Cancer Program within the Faculty of Medicine, Health and Human Sciences. He is also a Senior Staff Specialist in Medical Oncology at Westmead Hospital. His research focuses on urogenital cancers, including prostate, bladder, testicular, and kidney cancers, with a particular emphasis on clinical trials and pharmacogenomics.

Dr. Gurney has led over 150 clinical trials and published extensively in peer-reviewed journals, including the New England Journal of Medicine and Lancet Oncology. His work explores therapeutic monitoring of chemotherapy, targeted therapies, and safe dosing mechanisms for anticancer agents. He has secured multiple research grants and authored invited editorials on these topics.

Recent publications highlight his contributions to advanced renal cell carcinoma treatment, biomarker analyses, and novel drug combinations (e.g., lenvatinib/pembrolizumab). His projects span Phase I to III clinical trials, such as the JAVELIN Renal 101 trial and the ACRF Centre for Advanced Cancer Modelling.

Collaborations include global studies on immunotherapies like avelumab and pembrolizumab, alongside targeted therapies for metastatic prostate cancer. He advocates for therapeutic drug monitoring to optimize cancer treatment safety and efficacy.